BACKGROUND: Sarcomere mutations cause both dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM); however, the steps leading from mutation to disease are not well described. By studying mutation carriers before a clinical diagnosis develops, we characterize the early manifestations of sarcomere mutations in DCM and investigate how these manifestations differ from sarcomere mutations associated with HCM. METHODS AND RESULTS: Sixty-two genotyped individuals in families with sarcomeric DCM underwent clinical evaluation including strain echocardiography. The group included 12 subclinical DCM mutation carriers with normal cardiac dimensions and left ventricular ejection fraction (LVEF ≥55%), 21 overt DCM subjects, and 29 related mutation (-) normal controls. Results were compared with a previously characterized cohort of 60 subclinical HCM subjects (sarcomere mutation carriers without left ventricular hypertrophy). Systolic myocardial tissue velocity, longitudinal, circumferential, and radial strain, and longitudinal and radial strain rate were reduced by 10%-23% in subclinical DCM mutation carriers compared with controls (P<0.001 for all comparisons), after adjusting for age and family relations. No significant differences in diastolic parameters were identified comparing the subclinical and control cohorts. The opposite pattern of contractile abnormalities with reduced diastolic but preserved systolic function was seen in subclinical HCM. CONCLUSIONS: Subtle abnormalities in systolic function are present in subclinical DCM mutation carriers, despite normal left ventricular size and ejection fraction. In contrast, impaired relaxation and preserved systolic function appear to be the predominant early manifestations of sarcomere mutations that lead to HCM. These findings support the theory that the mutation's intrinsic impact on sarcomere function influences whether a dilated or hypertrophic phenotype develops.
BACKGROUND: Sarcomere mutations cause both dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM); however, the steps leading from mutation to disease are not well described. By studying mutation carriers before a clinical diagnosis develops, we characterize the early manifestations of sarcomere mutations in DCM and investigate how these manifestations differ from sarcomere mutations associated with HCM. METHODS AND RESULTS: Sixty-two genotyped individuals in families with sarcomeric DCM underwent clinical evaluation including strain echocardiography. The group included 12 subclinical DCM mutation carriers with normal cardiac dimensions and left ventricular ejection fraction (LVEF ≥55%), 21 overt DCM subjects, and 29 related mutation (-) normal controls. Results were compared with a previously characterized cohort of 60 subclinical HCM subjects (sarcomere mutation carriers without left ventricular hypertrophy). Systolic myocardial tissue velocity, longitudinal, circumferential, and radial strain, and longitudinal and radial strain rate were reduced by 10%-23% in subclinical DCM mutation carriers compared with controls (P<0.001 for all comparisons), after adjusting for age and family relations. No significant differences in diastolic parameters were identified comparing the subclinical and control cohorts. The opposite pattern of contractile abnormalities with reduced diastolic but preserved systolic function was seen in subclinical HCM. CONCLUSIONS:Subtle abnormalities in systolic function are present in subclinical DCM mutation carriers, despite normal left ventricular size and ejection fraction. In contrast, impaired relaxation and preserved systolic function appear to be the predominant early manifestations of sarcomere mutations that lead to HCM. These findings support the theory that the mutation's intrinsic impact on sarcomere function influences whether a dilated or hypertrophic phenotype develops.
Authors: Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart Journal: J Am Soc Echocardiogr Date: 2005-12 Impact factor: 5.251
Authors: Brage H Amundsen; Thomas Helle-Valle; Thor Edvardsen; Hans Torp; Jonas Crosby; Erik Lyseggen; Asbjørn Støylen; Halfdan Ihlen; João A C Lima; Otto A Smiseth; Stig A Slørdahl Journal: J Am Coll Cardiol Date: 2006-01-26 Impact factor: 24.094
Authors: M W Ashford; W Liu; S J Lin; P Abraszewski; S D Caruthers; A M Connolly; X Yu; S A Wickline Journal: Circulation Date: 2005-10-10 Impact factor: 29.690
Authors: Joachim P Schmitt; Edward P Debold; Ferhaan Ahmad; Amy Armstrong; Andrea Frederico; David A Conner; Ulrike Mende; Martin J Lohse; David Warshaw; Christine E Seidman; J G Seidman Journal: Proc Natl Acad Sci U S A Date: 2006-09-18 Impact factor: 11.205
Authors: Edward P Debold; J P Schmitt; J B Patlak; S E Beck; J R Moore; J G Seidman; C Seidman; D M Warshaw Journal: Am J Physiol Heart Circ Physiol Date: 2007-03-09 Impact factor: 4.733
Authors: Niall G Mahon; Ross T Murphy; Calum A MacRae; Alida L P Caforio; Perry M Elliott; William J McKenna Journal: Ann Intern Med Date: 2005-07-19 Impact factor: 25.391
Authors: Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier Journal: Cardiovasc Res Date: 2015-01-28 Impact factor: 10.787
Authors: Susan Cheng; Elizabeth L McCabe; Martin G Larson; Ming-Huei Chen; Ewa Osypiuk; Birgitta T Lehman; Plamen Stantchev; Jayashri Aragam; Scott D Solomon; Emelia J Benjamin; Ramachandran S Vasan Journal: Eur J Heart Fail Date: 2014-12-01 Impact factor: 15.534
Authors: Elham Kayvanpour; Farbod Sedaghat-Hamedani; Ali Amr; Alan Lai; Jan Haas; Daniel B Holzer; Karen S Frese; Andreas Keller; Katrin Jensen; Hugo A Katus; Benjamin Meder Journal: Clin Res Cardiol Date: 2016-08-30 Impact factor: 5.460
Authors: Jessica R Golbus; Megan J Puckelwartz; Lisa Dellefave-Castillo; John P Fahrenbach; Viswateja Nelakuditi; Lorenzo L Pesce; Peter Pytel; Elizabeth M McNally Journal: Circ Cardiovasc Genet Date: 2014-09-01